Mouse Monoclonal CDC2 Antibody

The CDC2 antibody targets the CDC2 protein, also known as CDK1 (cyclin-dependent kinase 1), a critical regulator of cell cycle progression. CDC2. first identified in *Saccharomyces cerevisiae*, is a serine/threonine kinase that partners with cyclin B to form the maturation-promoting factor (MPF), which drives the G2-to-M phase transition. It controls mitotic entry by phosphorylating substrates involved in nuclear envelope breakdown, chromatin condensation, and spindle assembly. Dysregulation of CDC2 activity is linked to genomic instability and cancer, as its overexpression or improper activation can lead to uncontrolled cell proliferation. Antibodies against CDC2 are widely used in research to study cell cycle dynamics, checkpoint mechanisms, and cancer biology. They enable detection of CDC2 expression levels, phosphorylation status (e.g., at Thr161 for activation or Tyr15/Thr14 for inhibition), and interactions with regulatory proteins. These tools are essential in techniques like Western blotting, immunofluorescence, and flow cytometry, aiding in the exploration of therapeutic strategies targeting cell cycle abnormalities. Commercial CDC2 antibodies are typically raised in rabbits or mice using peptide antigens corresponding to conserved regions of the human protein. Specific validation, including knockout controls, is recommended due to potential cross-reactivity with other CDK family members.